Compare MTN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTN | RYTM |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.8B |
| IPO Year | 1996 | 2017 |
| Metric | MTN | RYTM |
|---|---|---|
| Price | $150.93 | $108.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $162.58 | $131.14 |
| AVG Volume (30 Days) | ★ 719.4K | 637.5K |
| Earning Date | 06-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.27% | N/A |
| EPS Growth | 24.05 | ★ 28.34 |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $2,964,347,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $6.42 | $86.06 |
| P/E Ratio | $15.86 | ★ N/A |
| Revenue Growth | ★ 2.74 | N/A |
| 52 Week Low | $118.51 | $74.50 |
| 52 Week High | $165.50 | $122.20 |
| Indicator | MTN | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 55.70 |
| Support Level | $131.42 | $98.76 |
| Resistance Level | $153.18 | $113.03 |
| Average True Range (ATR) | 4.67 | 4.86 |
| MACD | -0.41 | -0.41 |
| Stochastic Oscillator | 47.12 | 79.05 |
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.